Cost utility Analysis of Adult Patients with Severe Aplastic Anemia Based on Single-center Cohort Study

Author:

chen lin1,fang liwei1,kuang zhexiang1,xu jing1,wang chuan1

Affiliation:

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood 4 Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 5 Chines

Abstract

Abstract Objective The purpose of this study is to objectively evaluate the efficacy of cyclosporine A + ALG and cyclosporine A + TPO-RA in the treatment of SAA patients, and to provide scientific data support for maximizing the therapeutic benefit of SAA patients. Method Cost-utility analysis was used to compare the quality of life adjusted years and total cost of the two schemes. The patient utility value was obtained from EQ-5D-3L and Japanese TTO conversion, and the total cost of treatment was obtained from electronic questionnaire survey and medical information data. Results A total of 26 adult patients were included in the study, including 17 with cyclosporine A + ALG and 9 with cyclosporine A + TPO-RA. In terms of QALY, patients with cyclosporine A + ALG regimen had higher intuitive feelings than those with cyclosporine A + TPO-RA regimen from admission to 6 months of follow-up, and the quality of life of patients with the former regimen was also significantly higher than that of the latter, with a difference of 0. 08 QALY (P < 0.01). In terms of total cost, the total cost of the former was twice that of the latter.Each QALY obtained by the two regimens was 687,000 yuan and 450,000 yuan, respectively.Compared with the cyclosporine A + TPO-RA regimen, the total cost of each QALY increased by the cyclosporine A + ALG regimen was 1.51 million yuan. Conclusion On the premise of ensuring the effectiveness of diagnosis and treatment, CsA + TPO-RA can be used as a good treatment option, which can reduce the economic pressure of SAA patients, reduce the burden of disease, reduce the pressure of medical insurance funds, and achieve multi-benefits.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3